Pharmaceutical News

RSS

Data demonstrates the effectiveness of NeuroAiD on neuronal and brain injuries

The January issue of "Neuropharmacology", publishes the article entitled "Neuroprotective and Neuroproliferative Activities of NeuroAiD", reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.

12 Feb 2010

Glycotex announces the expansion of patent portfolio in Advanced Wound Healing for GLYC-101

Glycotex, Inc. today announced the expansion of its patent portfolio in Advanced Wound Healing for its product candidate GLYC-101 currently in clinical phase 2 in the United States.

12 Feb 2010

Researchers develop dietary supplement to offset key symptom of ageing

Researchers at McMaster University have developed a cocktail of ingredients that forestalls major aspects of the aging process.

12 Feb 2010

Sun Knowledge to attend Annual Drug Benefit Conference in Phoenix

Sun Knowledge, Ltd., a leading Healthcare Insurance provider of Knowledge Process Outsourcing (KPO) services, will attend the Pharmacy Benefit Management Institute’s Annual Drug Benefit Conference in Phoenix, Az., from February 17-19.

12 Feb 2010

Low doses of antibiotics may serve as active mutagens and lead to multidrug resistance

Multidrug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) pose a major problem for patients, doctors, and the pharmaceutical industry. To combat such bacteria, it is critical to understand how resistance is developed in the first place. It is commonly thought that an incomplete course of antibiotics would lead to resistance to that particular antibiotic by allowing the bacteria to make adaptive changes under less stringent conditions.

12 Feb 2010

Sustamine L-Alanyl-L-Glutamine supplement increases performance in endurance exercise and activity

A clinical study by Dr. Jay Hoffman, PhD, professor and chair of the Department of Health and Exercise Science at the College of New Jersey, has shown Sustamine™ L-Alanyl-L-Glutamine, increases performance in endurance exercise and activity. The study was published on February 3, 2010, in the Journal of the International Society of Sports Nutrition (JISSN), a peer-reviewed journal covering various aspects of sports nutrition, supplementation, exercise metabolism, and/or scientific policies related to sports nutrition.

12 Feb 2010

Proving value a challenge for comparative effectiveness and pharmaceutical technologies

The Wall Street Journal reports that "an examination of one of the best-known examples of a comparative-effectiveness analysis shows how complicated such a seemingly straightforward idea can get" as officials look for savings in the health care system." One study, called Courage, "found that the most common heart surgery -- a $15,000 procedure that unclogs arteries using a small scaffold or stent -- usually yields no additional benefit when used with a cocktail of generic drugs in patients suffering from chronic chest pain."

12 Feb 2010

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, announced today that it has begun distributing and selling Cobroxin through mass food and drug retail chains in the Northeast, Southeast, Middle Atlantic and Midwest regions.

12 Feb 2010

Ulcerative colitis drug market to grow up to $2.1 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug market will nearly double from $1.2 billion in 2008 to $2.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

12 Feb 2010

Researchers identify potential drug candidate that halts tumor growth

A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position.

12 Feb 2010

Cancer drug could be effective for treating recurrent nose bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin.

12 Feb 2010

Scientists find single-dose of drug cures visceral leishmaniasis

A study has shown that a single infusion of Gilead Sciences' drug AmBisome, known generically as iposomal amphotericin B, cured nearly all patients with visceral leishmaniasis, or kala-azar, a parasitic infection, Reuters reports.

12 Feb 2010

Biological-based therapies are alternative medicines for women recovering from breast cancer

Biological-based therapies such as diet supplements and vitamins are the most popular complementary and alternative medicines for women recovering from breast cancer, according to a Michigan State University researcher working to create a support intervention for women in treatment for the disease.

12 Feb 2010

FDA grants approval for Abbott's antiretroviral medication Norvir

Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.

11 Feb 2010

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.

11 Feb 2010

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for intravenous (IV) acetaminophen.

11 Feb 2010

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration ("SFDA") to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of Influenza A and Influenza B. Zanamivir is marketed globally by GlaxoSmithKline under the trade name Relenza.

11 Feb 2010

Indiana's pharmaceutical research and manufacturing companies maintained steady growth in 2009

Indiana's contract pharmaceutical research and manufacturing companies continued to expand in 2009, despite challenges in the biopharmaceutical contract service sector due to the downturn in the economy, the prospect of healthcare reform and other market developments.

11 Feb 2010

Micromet outlines the design of registration study for blinatumomab in ALL

At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.

11 Feb 2010

Shenogen Pharma Group, Chemizon sign drug discovery collaboration agreement

Shenogen Pharma Group and Chemizon, a division of Optomagic Co. Ltd. today announced a drug discovery collaboration agreement to create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.

11 Feb 2010

Pharmaceutical News

Data demonstrates the effectiveness of NeuroAiD on neuronal and brain injuries

Glycotex announces the expansion of patent portfolio in Advanced Wound Healing for GLYC-101

Researchers develop dietary supplement to offset key symptom of ageing

Sun Knowledge to attend Annual Drug Benefit Conference in Phoenix

Low doses of antibiotics may serve as active mutagens and lead to multidrug resistance

Sustamine L-Alanyl-L-Glutamine supplement increases performance in endurance exercise and activity

Proving value a challenge for comparative effectiveness and pharmaceutical technologies

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

Ulcerative colitis drug market to grow up to $2.1 billion in 2018

Researchers identify potential drug candidate that halts tumor growth

Cancer drug could be effective for treating recurrent nose bleeds

Scientists find single-dose of drug cures visceral leishmaniasis

Biological-based therapies are alternative medicines for women recovering from breast cancer

FDA grants approval for Abbott's antiretroviral medication Norvir

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Indiana's pharmaceutical research and manufacturing companies maintained steady growth in 2009

Micromet outlines the design of registration study for blinatumomab in ALL

Shenogen Pharma Group, Chemizon sign drug discovery collaboration agreement

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News